PHXM Stock Overview
A biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
PHAXIAM Therapeutics S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.87 |
| 52 Week High | €3.08 |
| 52 Week Low | €1.50 |
| Beta | 1.7 |
| 1 Month Change | 5.06% |
| 3 Month Change | 17.61% |
| 1 Year Change | -34.62% |
| 3 Year Change | -88.03% |
| 5 Year Change | -96.47% |
| Change since IPO | -98.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHXM | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 0% | 1.6% | -0.7% |
| 1Y | -34.6% | -17.2% | 0.7% |
Return vs Industry: PHXM underperformed the French Biotechs industry which returned -17.5% over the past year.
Return vs Market: PHXM underperformed the French Market which returned 2.9% over the past year.
Price Volatility
| PHXM volatility | |
|---|---|
| PHXM Average Weekly Movement | 4.9% |
| Biotechs Industry Average Movement | 7.5% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 10.0% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: PHXM has not had significant price volatility in the past 3 months compared to the French market.
Volatility Over Time: PHXM's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 68 | Thibaut Fayet | www.phaxiam.com |
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa.
PHAXIAM Therapeutics S.A. Fundamentals Summary
| PHXM fundamental statistics | |
|---|---|
| Market cap | €18.73m |
| Earnings (TTM) | -€21.92m |
| Revenue (TTM) | €2.14m |
8.7x
P/S Ratio-0.9x
P/E RatioIs PHXM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHXM income statement (TTM) | |
|---|---|
| Revenue | €2.14m |
| Cost of Revenue | €0 |
| Gross Profit | €2.14m |
| Other Expenses | €24.06m |
| Earnings | -€21.92m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 13, 2025
| Earnings per share (EPS) | -2.19 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,023.91% |
| Debt/Equity Ratio | 51.8% |
How did PHXM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/20 02:40 |
| End of Day Share Price | 2025/02/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PHAXIAM Therapeutics S.A. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mathieu Chabert | Bryan Garnier & Co |
| Guillaume Cuvillier | Gilbert Dupont |
| Philippa Gardner | Jefferies LLC |